Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics discovery and development, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics discovery and development, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 10:30 a.m. ET.
The event will be accessible through a live webcast on the company's investor relations website at ir.enliventherapeutics.com. Interested parties who cannot attend the live session can access the archived recording, which will remain available for 90 days after the event's conclusion.
Details
News Market Reaction – ELVN
The recorded move for ELVN in the trading session of this news was +0.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in
View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-302384762.html
SOURCE Enliven Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.